Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target
This study provides insights into the molecular mechanisms underlying PAAD and establishes a theoretical foundation for the development of CAF-targeting therapeutic strategies.
Authors
- X. Zhang
- D C Zhang
- Min Lv (ORCID: https://orcid.org/0000-0003-2962-2658)
- Hu Xu
- Juan null Ran
- Zhihua null Shui
- Feng null Cao
- Endi null Zhou
- Pengwei null Cao
- Fubao null Liu
- Wenjing null Ding
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-12-17
- DOI
- https://doi.org/10.31083/fbl46316
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00